ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.250
+0.060 (2.74%)
At close: Aug 29, 2025, 4:00 PM
2.250
0.00 (0.00%)
After-hours: Aug 29, 2025, 4:10 PM EDT
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover ProQR Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $8.88, which forecasts a 294.67% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $14.
Price Target: $8.88 (+294.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ProQR Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 2 | 3 | 4 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +77.78% | Aug 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $8 | Buy | Reiterates | $8 | +255.56% | Jun 27, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $8 | Buy | Reiterates | $8 | +255.56% | Jun 27, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $9 | Buy | Maintains | $15 → $9 | +300.00% | May 13, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $5 | Buy | Initiates | $5 | +122.22% | Apr 29, 2025 |
Financial Forecast
Revenue This Year
16.89M
from 19.55M
Decreased by -13.57%
Revenue Next Year
12.85M
from 16.89M
Decreased by -23.96%
EPS This Year
-0.40
from -0.32
EPS Next Year
-0.48
from -0.40
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 30.5M | 21.5M | |||
| Avg | 16.9M | 12.8M | |||
| Low | 8.2M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 55.9% | 27.4% | |||
| Avg | -13.6% | -24.0% | |||
| Low | -58.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.25 | -0.34 | |
| Avg | -0.40 | -0.48 | |
| Low | -0.50 | -0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.